HIV, Buprenorphine, and the Criminal Justice System
Status:
Completed
Trial end date:
2016-11-30
Target enrollment:
Participant gender:
Summary
The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a
longitudinal, non-randomized, observational study design. The population under study consists
of individuals living with HIV who are dependent on opioids.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborators:
George Mason University Howard University National Institute on Drug Abuse (NIDA)
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone